Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Moderna, Inc.
  6. News
  7. Summary
    MRNA   US60770K1079

MODERNA, INC.

(MRNA)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Moderna : Heart inflammation in young men higher than expected after Pfizer, Moderna vaccines -U.S. CDC

06/10/2021 | 11:46am EDT

June 10 (Reuters) - A higher-than-expected number of young men have experienced heart inflammation after their second dose of the mRNA COVID-19 shots from Pfizer/BioNTech and Moderna, according to data from two vaccine safety monitoring systems, the U.S. Centers for Disease Control and Prevention (CDC) said on Thursday.

The CDC and other health regulators have been investigating heart inflammation cases after Israel’s Health Ministry reported that it had found a likely link to the condition in young men who received Pfizer’s COVID-19 vaccine.

The agency said it is still assessing the risk from the condition and has not yet concluded that there was a causal relationship between the vaccines and cases of myocarditis or pericarditis.

While some patients required hospitalization, most have fully recovered from their symptoms, the CDC said.

More than half of the cases reported to the U.S. Vaccine Adverse Event Reporting System (VAERS) after people had received their second dose of either the Pfizer/BioNTech or Moderna vaccines were in people between the ages of 12 and 24, the CDC said. Those age groups accounted for less than 9% of doses administered.

"We clearly have an imbalance there," Dr. Tom Shimabukuro, deputy director of the CDC's Immunization Safety Office, said in a presentation https://www.fda.gov/media/150054/download to an advisory committee to the U.S. Food and Drug Administration meeting on Thursday.

The overwhelming majority of the cases have occurred within a week of vaccination, Shimabukuro said.

There were 283 observed cases of heart inflammation after the second vaccine dose in those aged 16 to 24 in the VAERS data. That compares with expectations of 10-to-102 cases for that age range based on U.S. population background incidence rates, the CDC said.

Shimabukuro said there was a predominance of males in younger age groups among the reported heart inflammation cases.

The median age of patients who experienced the inflammation after a second vaccine dose was 24, according to the VAERS data. Just under 80% of the cases were in men.

Shimabukuro also said the Vaccine Safety Datalink (VSD) - another safety monitoring system - showed an increased incidence of heart inflammation in 16 to 39 year olds after their second shot when compared to the rate observed after the first dose.

Pfizer said it supports the CDC's assessment of the heart inflammation cases, noting that "the number of reports is small given the number of doses administered."

About 130 million people in the United States have received both doses of one of the mRNA vaccines.

"It is important to understand that a careful assessment of the reports is ongoing and it has not been concluded that the mRNA COVID-19 vaccines cause myocarditis or pericarditis," the company said in a statement.

Moderna said it also has not established a causal association with the condition and its vaccine. It said it is actively working with public health and regulatory authorities to further assess the issue.

The CDC said it will hold a meeting of its Advisory Committee on Immunization Practices next week to further evaluate the evidence and assess the risk of myocarditis following mRNA vaccination for COVID-19. (Reporting by Michael Erman in Maplewood, N.J. and Manojna Maddipatla in Bengaluru; Editing by Bill Berkrot)


© Reuters 2021
Stocks mentioned in the article
ChangeLast1st jan.
MODERNA, INC. -4.21% 212.04 Delayed Quote.111.89%
PFIZER, INC. -1.41% 39.05 Delayed Quote.7.61%
All news about MODERNA, INC.
03:51pMODERNA  : U.S. CDC Says Administered 319,872,053 Doses Of Covid-19 Vaccine As O..
RE
03:28pTHE LATEST : German Chancellor switches vaccine for 2nd dose
AQ
03:12pMODERNA  : NIH begins clinical trial testing COVID-19 vaccine in pregnant women
RE
01:19pStocks Mixed Midday as Defensives Trade Lower; Oil Advances as Crude Stockpil..
MT
01:04pMIDDAY REPORT : US Stocks Mixed as Defensives Trade Lower; Oil Advances as Crude..
MT
12:02pMODERNA  : 'Likely link' between rare heart inflammation and Pfizer, Moderna vac..
RE
11:49aUS' CDC To Study Possible Link Between Heart Inflammation And Pfizer/BioNTech..
MT
10:39aGSK's drugs arm to get $11 billion booster from consumer spin-off
RE
10:17aMODERNA  : European Commission Purchases Additional 150 Million Doses of Moderna..
AQ
08:58aMODERNA  : Japan to halt company applications for workplace vaccinations
AQ
More news
Financials (USD)
Sales 2021 18 632 M - -
Net income 2021 10 719 M - -
Net cash 2021 11 520 M - -
P/E ratio 2021 8,97x
Yield 2021 -
Capitalization 88 882 M 88 882 M -
EV / Sales 2021 4,15x
EV / Sales 2022 4,28x
Nbr of Employees 1 300
Free-Float 90,3%
Chart MODERNA, INC.
Duration : Period :
Moderna, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MODERNA, INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 17
Last Close Price 221,36 $
Average target price 168,87 $
Spread / Average Target -23,7%
EPS Revisions
Managers and Directors
NameTitle
Stéphane Bancel Chief Executive Officer & Director
Stephen Hoge President
David W. Meline Chief Financial Officer
Noubar B. Afeyan Chairman
Juan Andres Chief Technical Operations & Quality Officer
Sector and Competitors
1st jan.Capitalization (M$)
MODERNA, INC.111.89%88 882
LONZA GROUP AG14.06%52 367
IQVIA HOLDINGS INC.36.17%46 761
CELLTRION, INC.-21.59%32 903
SEAGEN INC.-9.40%28 797
HANGZHOU TIGERMED CONSULTING CO., LTD20.45%25 469